Shandong Lukang PharmaceuticalLtd Valuation
Is 600789 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 600789 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 600789 (CN¥8.81) is trading above our estimate of fair value (CN¥2.2)
Significantly Below Fair Value: 600789 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 600789?
Key metric: As 600789 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 600789's PE Ratio? | |
|---|---|
| PE Ratio | 19.8x |
| Earnings | CN¥400.68m |
| Market Cap | CN¥7.92b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 15.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 600789's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 23.1x | ||
600557 Jiangsu Kanion PharmaceuticalLtd | 15.2x | 18.2% | CN¥8.3b |
601089 Beijing Foyou PharmaLTD | 14.8x | n/a | CN¥7.6b |
300119 Tianjin Ringpu Bio-TechnologyLtd | 22.2x | 18.3% | CN¥9.4b |
300725 PharmaBlock Sciences (Nanjing) | 40.4x | 28.5% | CN¥7.1b |
600789 Shandong Lukang PharmaceuticalLtd | 19.8x | n/a | CN¥7.9b |
Price-To-Earnings vs Peers: 600789 is good value based on its Price-To-Earnings Ratio (19.8x) compared to the peer average (23.1x).
Price to Earnings Ratio vs Industry
How does 600789's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 600789 is good value based on its Price-To-Earnings Ratio (19.8x) compared to the CN Pharmaceuticals industry average (32x).
Price to Earnings Ratio vs Fair Ratio
What is 600789's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 19.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 600789's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sichuan Kelun Pharmaceutical
CN¥51.9b
Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.
2422
CN¥32.72
7D
7.3%
1Y
15.1%
China Resources Sanjiu Medical & Pharmaceutical
CN¥57.9b
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
999
CN¥45.11
7D
-1.3%
1Y
19.5%
China Resources Sanjiu Medical & Pharmaceutical
CN¥57.9b
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
999
CN¥45.11
7D
-1.3%
1Y
19.5%